Valuation: Interpace Biosciences, Inc.

Market Cap 3.59Cr 3.15Cr 2.96Cr 2.7Cr 5.05Cr 343.47Cr 5.09Cr 36Cr 14Cr 175.11Cr 13Cr 13Cr 567.76Cr P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 3.45Cr 3.03Cr 2.85Cr 2.6Cr 4.87Cr 330.81Cr 4.9Cr 34Cr 13Cr 168.66Cr 13Cr 13Cr 546.83Cr EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+0.31%
1 week+0.31%
Current month-14.53%
1 month-15.02%
3 months-22.98%
6 months-24.43%
Current year+5.19%
1 week 6.45
Extreme 6.45
6.65
1 month 5.97
Extreme 5.9732
7.85
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
50.25
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Exercice

Chief Financial Officer

13,85,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%+0.31%+57.75%+12.52% 3.59Cr
-0.03%+13.16%+126.11%+752.88% 5.63TCr
-2.43%-6.33%+8.59%+48.17% 2.47TCr
-0.26%-3.39%-12.81%-38.12% 661.52Cr
-0.97%-3.39%-5.22%+165.16% 576.14Cr
+0.89%+0.81%+17.44%+62.64% 335.6Cr
-6.17%-12.54%-29.86%+2,273.26% 254.09Cr
-2.81%-3.06%+125.83%+51.11% 235.88Cr
+17.72%+3.00%+36.75%+47.78% 232.3Cr
+0.03%+7.03%-0.38%-53.40% 197.8Cr
Average +0.62%-0.38%+32.42%+332.20% 1.06TCr
Weighted average by Cap. -0.45%+5.05%+71.42%+475.78%

Financials

2024 2025
Net sales 4.69Cr 4.12Cr 3.87Cr 3.54Cr 6.61Cr 449.51Cr 6.66Cr 47Cr 18Cr 229.18Cr 18Cr 17Cr 743.05Cr 3.87Cr 3.4Cr 3.2Cr 2.92Cr 5.46Cr 370.98Cr 5.5Cr 38Cr 15Cr 189.14Cr 15Cr 14Cr 613.24Cr
Net income 67.02L 58.82L 55.29L 50.55L 94.47L 64Cr 95.17L 6.64Cr 2.57Cr 33Cr 2.52Cr 2.46Cr 106.12Cr 2.46Cr 2.16Cr 2.03Cr 1.85Cr 3.46Cr 235.41Cr 3.49Cr 24Cr 9.44Cr 120.02Cr 9.23Cr 9.03Cr 389.13Cr
Net Debt 43.95L 38.57L 36.26L 33.15L 61.95L 42Cr 62.41L 4.36Cr 1.69Cr 21Cr 1.65Cr 1.61Cr 70Cr -13.22L -11.6L -10.91L -10L -18.63L -13Cr -18.77L -1.31Cr -50.79L -6.46Cr -49.65L -48.56L -21Cr
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
22/26/22 $6.470 +0.31% 1,489
18/26/18 $6.450 0.00% 723
17/26/17 $6.450 0.00% 170
16/26/16 $6.450 -0.77% 512
15/26/15 $6.500 +3.17% 676

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXGD Stock